Clinical Study Aimed At Evaluating the Safety and Efficacy of Tear Substitute Formulations in the Treatment of Dry Eye Disease.

NCT06633471 | Not Yet Recruiting Early Phase 1 DMC FDA Drug

• 1 other identifier: CL001
• Study Type: interventional
• Target: 175
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical study is aimed at evaluating the safety and effectiveness of 2 test formulations (Rain and Mist), against an approved over-the-counter formulation (Systane Ultra) and a placebo (saline), in the treatment of moderate dry eye disease.

Conditions

Dry Eye Disease (DED)

Outcome Measures

Primary Outcomes (5)

• Schirmer's Test

  Mean change in Schirmer's Test Score (STS) from pre-instillation of IP to 5 minutes post-instillation of IP at Visits 1 and 2

  4 weeks

• Tear Film Break Up Time (TFBUT)

  Mean change in Tear Film Break Up Time (TFBUT) from baseline to post- instillation of IP at each of Visits 1 and 2

  4 weeks

• Corneal Fluorescein Staining

  Mean change from Baseline in Corneal Fluorescein Staining at Visits 1 and 2

  4 weeks

• Conjunctival Staining

  Mean change from Baseline in Conjunctival Staining at Visits 1 and 2

  4 weeks

• Ocular Redness

  Ocular redness, as evaluated by the Investigator, at Baseline at Visits 1 and 2 (0-4 unit scale, allowing half unit increments) assessed pre-dose at each visit

  4 weeks

Secondary Outcomes (5)

• Secondary Efficacy Parameters

  4 weeks

• Adverse Events

  4 weeks

• Slit Lamp Findings

  4 weeks

• IOP

  4 weeks

• Fundoscopy

  4 weeks

Other Outcomes (1)

• Tolerability Measures

  4 weeks

Study Arms (4)

30 subjects assigned to receive Rain

EXPERIMENTAL

Rain is one of the test formulations being evaluated for safety and efficacy in treating DED.

Drug: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).

30 patients assigned to receive saline

PLACEBO COMPARATOR

Saline is the placebo in this study.

Drug: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).

30 subjects assigned to receive Mist

EXPERIMENTAL

Mist is one of the test formulations being evaluated for safety and efficacy in treating DED.

Drug: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).

30 patients assigned to receive Systane Ultra

ACTIVE COMPARATOR

Systane Ultra is the approved OTC formulation used to treat DED and the comparator for Rain and Mist.

Drug: Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo).

Interventions

Two test formulations for the treatment of DED are being compared against the approved OTC formulation (Systane Ultra) and saline (placebo). DRUG

Rain and Mist are the test formulations. Systane Ultra is an approved OTC formulation. Saline is the placebo.

30 patients assigned to receive Systane Ultra; 30 patients assigned to receive saline; 30 subjects assigned to receive Mist; 30 subjects assigned to receive Rain

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Each subject must:
• Be at least 18 years of age at the Screening Visit;
• Of either gender and any race;
• Be willing and able to follow all instructions and attend all study visits;
• Have ALL of the following in the study eye1 at the Screening Visit:
• A corneal fluorescein staining score of ≥ 2 in at least one corneal region OR have a sum of ≥ 4 in all corneal regions
• A baseline Schirmer's Test (with topical anesthesia) Score of ≥ 2 millimeters (mm)/ and ≤ 10 mm/5 minutes
• A physician's diagnosis of Dry Eye Disease
• Have normal lid/lash anatomy, blinking function and closure as determined by the Investigator;
• Be literate and able to complete questionnaires independently;
• Have sufficient hand strength, in the opinion of the Investigator, to be able to independently administer the study drug;
• For females capable of becoming pregnant, agree to have urine pregnancy testing performed at screening (must be negative) and exit visits; must not be lactating; and must agree to use a medically acceptable form of birth control throughout the study. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months), or have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy).

You may not qualify if:

• Each subject must not:
• Have a known hypersensitivity to any of the procedural agents or study drug components, or have previously used the study drug;
• Have clinically significant corneal epithelial defects at Visit 1, prior to performing Schirmer's Test;
• Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months, or refractive surgery (e.g., laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1;
• Have had blepharoplasty in either eye;
• Have had a corneal transplant in either eye;
• Have used Restasis® or Xiidra® in the past 60 days;
• Be using any ocular medications, other than the study treatment, within 7 days prior to Visit 1 and throughout the study treatment period. This includes both therapeutic and lubricant eye drops that could potentially interfere with the study outcomes, by either exacerbating or alleviating the symptoms of dry eye disease.
• Have used contact lenses within 7 days prior to Visit 1 or anticipate the use of contact lenses during the study treatment period;
• Have any form of punctal or intracanalicular occlusion;
• Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed;
• Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study, or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.);
• Have active or uncontrolled, severe:
• Systemic allergy
• Chronic seasonal allergies at risk of being active during the study

Sponsors & Collaborators

• PS Therapy Inc.: lead

Study Sites (1)

Warrens Eye Care Centre

Bridgetown, Barbados

Location

MeSH Terms

Conditions

Dry Eye Syndromes

Condition Hierarchy (Ancestors)

Lacrimal Apparatus Diseases; Eye Diseases

Central Study Contacts

Nigel Barker, Dr.

CONTACT

246-230-4146; kerlach@yahoo.com

Jessica Walcott

CONTACT

246-420-6795; barbrook2001@hotmail.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2024
• First Posted: October 9, 2024
• Study Start: November 4, 2024
• Primary Completion: February 28, 2025
• Study Completion: April 30, 2025
• Last Updated: October 9, 2024

Record last verified: 2024-10

Locations

BA (1)